韋爾股份(603501.SH):華清龍芯等股東已合計減持1.2595%的股份
格隆匯 3 月 12日丨韋爾股份(603501.SH)公佈,公司於近日收到公司股東嘉興華清龍芯豪威股權投資合夥企業(有限合夥)(“華清龍芯”)、嘉興華清銀杏豪威股權投資合夥企業(有限合夥)(“華清銀杏”)、北京華清博廣創業投資有限公司(“華清博廣”)的通知,華清龍芯、華清銀杏、華清博廣(以下合稱“信息披露義務人”)為同一實際控制人控制的企業,互為一致行動人。
信息披露義務人在2020年9月4日至2021年3月11日期間,通過集中競價及大宗交易方式累計減持公司股份1092.7088萬股,佔公司總股本的1.2595%。此次權益變動後,信息披露義務人持有公司股份比例低於5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.